Valuation : Cocrystal Pharma, Inc.

Market Cap 22.73M 19.54M 18.39M 16.78M 31.31M 2.15B 31.48M 218M 84.28M 1.1B 85.36M 83.49M 3.51B P/E 2026 *
-1.71x
P/E 2027 * -2.03x
Enterprise Value 22.73M 19.54M 18.39M 16.78M 31.31M 2.15B 31.48M 218M 84.28M 1.1B 85.36M 83.49M 3.51B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
34.29%
Yield 2026 *
-
Yield 2027 * -
1 day+4.42%
1 week+5.36%
Current month+1.72%
1 month+11.32%
3 months+16.83%
6 months+16.83%
Current year+20.53%
1 week 1.1
Extreme 1.1
1.2
1 month 1.06
Extreme 1.06
1.22
Current year 0.76
Extreme 0.76
2.03
1 year 0.76
Extreme 0.76
2.67
3 years 0.76
Extreme 0.76
3.26
5 years 0.76
Extreme 0.76
13.38
10 years 0.76
Extreme 0.76
190.8
Manager TitleAgeSince
Chief Executive Officer 64 03/06/2026
Chief Executive Officer 59 27/05/2021
Chief Executive Officer 66 27/05/2021
Director TitleAgeSince
Director/Board Member 89 02/01/2014
Chairman 79 27/05/2021
Director/Board Member 65 02/01/2014
Date Insider Type Main position Quantity % Market Cap. Importance
05/08/26 Buy

Director

10,000 0.0725%
03/08/26 Buy

Director

75,000 0.5440%
03/06/26 Free

Chief Executive Officer

235,000 1.7044%
Change 5-day change 1-year change 3-year change Capi.($)
+4.42%+5.36%-21.33%-42.72% 22.73M
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.41%-2.30%+33.53%+78.63% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
+0.45%+0.57%+31.49%+15.97% 25.8B
+1.12%+0.84%+24.50%-17.84% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
+0.33%-0.69%-6.48%+526.89% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
Average +0.57%+1.55%+37.06%+156.78% 27.78B
Weighted average by Cap. +0.29%+0.46%+38.68%+141.46%

Financials

2026 *2027 *
Net sales - -
Net income -11.3M -9.72M -9.14M -8.34M -15.57M -1.07B -15.65M -108M -41.9M -548M -42.43M -41.51M -1.74B -11.5M -9.89M -9.3M -8.49M -15.84M -1.09B -15.92M -110M -42.64M -557M -43.18M -42.24M -1.77B
Net Debt - -
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
08/09/26 $1.180 +4.42% 61,385
04/09/26 $1.130 0.00% 43,422
03/09/26 $1.130 -2.59% 29,247
02/09/26 $1.160 +3.57% 56,683
01/09/26 $1.120 -3.45% 34,756
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.180USD
Average target price
9.000USD
Spread / Average Target
+662.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COCP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!